ハッチンソン・ギルフォード・プロジェリア症候群（HGPS）の世界市場レポート 2025年

ハッチンソン・ギルフォード・プロジェリア症候群（HGPS）市場規模は、今後数年間で力強い成長が見込まれます。2029年の年間平均成長率（CAGR）は8.8％で、1,492億2,000万米ドルに成長します。予測期間における成長の原動力となるのは、研究と新規治療開発のための資金提供の増加、早老症の有病率の上昇、世界のヘルスケア支出の増加、新規治療アプローチの採用、早期診断に対する需要の高まりなどです。この期間に予想される主な動向には、技術の発展、標的療法の開発、次世代シーケンシング（NGS）技術の向上、バイオマーカーの同定、ドラッグデリバリーシステムの進歩などがあります。

新しい治療法の研究開発資金の増加は、ハッチンソン・ギルフォード・プロジェリア症候群（HGPS）市場の成長を促進すると予想されます。研究開発資金とは、イノベーションの促進、科学的知識の向上、技術的ソリューションの進歩に割り当てられる財源を指します。このような資金の増加は、革新的な治療に対する需要の高まりやヘルスケアの進歩に対する政府の支援などの要因によるものです。研究開発への投資拡大は、臨床試験を支援し新規治療法の開発を促進することで、ハッチンソン・ギルフォード早老症候群に対する治療の進歩を加速させる。また、この病気の遺伝的起源の理解を進め、的を絞った解決策の創出を可能にします。例えば、2024年4月、英国の政府機関である国家統計局によると、2022年の英国政府の研究開発（R&D）に対する純支出は10.5％増加し、2021年の140億ポンド（158億8,000万米ドル）から155億ポンド（175億9,000万米ドル）に達しました。その結果、研究開発資金の増加がハッチンソン・ギルフォード・プロジェリア症候群（HGPS）市場の成長に寄与しています。

ハッチンソン・ギルフォード・プロジェリア症候群（HGPS）市場の主要企業は、治療効果を高め、罹患患者の疾患進行を遅らせるために、先進的なファルネシルトランスフェラーゼ阻害剤の開発を優先しています。ファルネシルトランスフェラーゼ阻害剤は、タンパク質の修飾を担う酵素であるファルネシルトランスフェラーゼを阻害する薬剤であり、細胞の異常増殖や老化を防ぐのに役立ちます。例えば、2022年7月、米国のバイオ医薬品会社であるアイガー・バイオファーマシューティカルズ（Eiger BioPharmaceuticals）は、ゾキンビー（Zokinvy）の販売承認を欧州委員会から取得し、小児および若年成人におけるハッチンソン・ギルフォード・プロジェリア症候群（HGPS）および処理不全性プロジェロイドラミノパチー（PL）に対する欧州初で唯一の承認治療薬となりました。経口疾患修飾薬であるゾキンヴィーは、臨床試験において死亡リスクを72％減少させ、平均4.3年の延命効果を示しました。欧州委員会の集中承認は、EU加盟27カ国すべてとアイスランド、リヒテンシュタイン、ノルウェーに適用されます。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- マクロ経済シナリオ金利、インフレ、地政学、新型コロナウイルス感染症の影響と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界ハッチンソン・ギルフォード・プロジェリア症候群（HGPS） PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界のハッチンソン・ギルフォード・プロジェリア症候群（HGPS）市場：成長率分析
• 世界のハッチンソン・ギルフォード・プロジェリア症候群（HGPS）市場の実績：規模と成長, 2019-2024
• 世界のハッチンソン・ギルフォード・プロジェリア症候群（HGPS）市場の予測：規模と成長, 2024-2029, 2034F
• 世界ハッチンソン・ギルフォード・プロジェリア症候群（HGPS）総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界のハッチンソン・ギルフォード・プロジェリア症候群（HGPS）市場治療の種類別、実績と予測, 2019-2024, 2024-2029F, 2034F
• ファルネシルトランスフェラーゼ阻害剤（ゾキンビー（ロナファルニブ））
• 低用量アスピリン
• 理学療法と作業療法
• 補聴器
• 遺伝カウンセリング
• その他の治療の種類
• 世界のハッチンソン・ギルフォード・プロジェリア症候群（HGPS）市場：投与経路別、実績と予測, 2019-2024, 2024-2029F, 2034F
• オーラル
• 注射剤
• 静脈内
• 経皮
• 世界のハッチンソン・ギルフォード・プロジェリア症候群（HGPS）市場作用機序別、実績と予測, 2019-2024, 2024-2029F, 2034F
• アンチセンスオリゴヌクレオチド
• Crispr-cas9遺伝子編集
• リボ核酸（RNA）干渉
• 標的ドラッグデリバリーシステム
• 世界のハッチンソン・ギルフォード・プロジェリア症候群（HGPS）市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• 専門クリニック
• 学術研究機関
• その他のエンドユーザー
• 世界のハッチンソン・ギルフォード・プロジェリア症候群（HGPS）市場ファルネシルトランスフェラーゼ阻害剤（ゾキンビ（ロナファルニブ））の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• ロナファルニブ単剤療法
• 他の薬剤との併用療法
• 世界のハッチンソン・ギルフォード・プロジェリア症候群（HGPS）市場低用量アスピリンの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 心血管保護
• 抗炎症療法
• 世界のハッチンソン・ギルフォード・プロジェリア症候群（HGPS）市場理学療法と作業療法の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 移動支援とリハビリテーション
• 関節と骨の健康管理
• 日常生活のための補助器具
• 世界のハッチンソン・ギルフォード・プロジェリア症候群（HGPS）市場補聴器の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 従来の補聴器
• 骨伝導補聴器（BAHA）
• 人工内耳
• 世界のハッチンソン・ギルフォード・プロジェリア症候群（HGPS）市場遺伝カウンセリングの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 家族遺伝子検査
• 遺伝的リスク評価
• 出生前カウンセリングとガイダンス
• 世界のハッチンソン・ギルフォード・プロジェリア症候群（HGPS）市場、その他の治療タイプのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 幹細胞療法
• 遺伝子編集と治療
• 栄養サポートと管理

第7章 地域別・国別分析

• 世界のハッチンソン・ギルフォード・プロジェリア症候群（HGPS）市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界のハッチンソン・ギルフォード・プロジェリア症候群（HGPS）市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• ハッチンソン・ギルフォード・プロジェリア症候群（HGPS）市場：競合情勢
• ハッチンソン・ギルフォード・プロジェリア症候群（HGPS）市場：企業プロファイル
  • National Institutes of Health（NIH）Overview, Products and Services, Strategy and Financial Analysis
  • Mount Sinai Overview, Products and Services, Strategy and Financial Analysis
  • Johns Hopkins Hospital Overview, Products and Services, Strategy and Financial Analysis
  • Duke University Overview, Products and Services, Strategy and Financial Analysis
  • Mayo Foundation for Medical Education and Research Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Cleveland Clinic
• Children's Hospital of Philadelphia
• St. Jude Children's Research Hospital
• Cincinnati Children's Hospital Medical Center
• University of Maryland
• Boston Children's Hospital
• Children's Hospital Los Angeles
• Harvard Medical School
• The Scripps Research Institute
• Blueprint Genetics
• Medicover Hospitals
• Sentynl Therapeutics
• UCSF Helen Diller Family Comprehensive Cancer Center
• Progeria Research Foundation
• AnGes MG Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• ハッチンソン・ギルフォード・プロジェリア症候群（HGPS）市場2029：新たな機会を提供する国
• ハッチンソン・ギルフォード・プロジェリア症候群（HGPS）市場2029：新たな機会を提供するセグメント
• ハッチンソン・ギルフォード・プロジェリア症候群（HGPS）市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Hutchinson-Gilford Progeria Syndrome (HGPS), commonly known as progeria, is an extremely rare and fatal genetic condition that causes rapid aging in children. It is triggered by mutations in the LMNA gene, resulting in symptoms such as growth delays, hair loss, premature skin wrinkling, and cardiovascular complications. The average life expectancy of individuals with progeria is around 14.5 years.

The primary treatments for Hutchinson-Gilford Progeria Syndrome (HGPS) include farnesyltransferase inhibitors (such as Zokinvy (lonafarnib)), low-dose aspirin, physical and occupational therapy, hearing aids, genetic counseling, and other supportive therapies. Farnesyltransferase inhibitors such as Zokinvy (lonafarnib) work by blocking the enzyme responsible for protein modification, providing a targeted treatment that may help slow premature aging in affected children. These treatments are administered through various methods, including oral, injectable, intravenous, and transdermal routes, utilizing mechanisms such as antisense oligonucleotides, CRISPR-Cas9 gene editing, RNA interference, and targeted drug delivery systems. The treatment is utilized across multiple healthcare settings, including hospitals, specialty clinics, academic and research institutes, and other medical facilities.

The hutchinson-gilford progeria syndrome (HGPS) market research report is one of a series of new reports from The Business Research Company that provides hutchinson-gilford progeria syndrome (HGPS) market statistics, including the hutchinson-gilford progeria syndrome (HGPS) industry global market size, regional shares, competitors with the hutchinson-gilford progeria syndrome (HGPS) market share, detailed hutchinson-gilford progeria syndrome (HGPS) market segments, market trends, and opportunities, and any further data you may need to thrive in the hutchinson-gilford progeria syndrome (HGPS) industry. This hutchinson-gilford progeria syndrome (HGPS) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The hutchinson-gilford progeria syndrome (HGPS) market size has grown strongly in recent years. It will grow from $97.63 billion in 2024 to $106.56 billion in 2025 at a compound annual growth rate (CAGR) of 9.1%. The growth during the historic period can be attributed to increased awareness of rare genetic disorders, greater funding for progeria research, the expansion of genetic testing, rising government initiatives for rare diseases, and the growing global prevalence of genetic disorders.

The hutchinson-gilford progeria syndrome (HGPS) market size is expected to see strong growth in the next few years. It will grow to $149.22 billion in 2029 at a compound annual growth rate (CAGR) of 8.8%. The projected growth in the forecast period is driven by increased funding for research and the development of new therapies, a rising prevalence of progeria, higher global healthcare expenditure, the adoption of novel therapeutic approaches, and a growing demand for early diagnosis. Key trends expected in this period include technological advancements, the development of targeted therapies, improvements in next-generation sequencing (NGS) technologies, the identification of biomarkers, and advancements in drug delivery systems.

The rise in funding for research and development of new therapies is expected to drive the growth of the Hutchinson-Gilford Progeria Syndrome (HGPS) market. Research and development funding refers to financial resources allocated to fostering innovation, enhancing scientific knowledge, and advancing technological solutions. The increase in such funding is attributed to factors such as the growing demand for innovative treatments and government support for healthcare advancements. Greater investment in research and development accelerates progress in treating Hutchinson-Gilford Progeria Syndrome by supporting clinical trials and promoting the development of novel therapies. It also advances the understanding of the genetic origins of the disease and enables the creation of targeted solutions. For example, in April 2024, the Office for National Statistics, a UK-based government agency, reported that in 2022, the UK government's net expenditure on research and development (R&D) increased by 10.5%, reaching £15.5 billion ($17.59 billion), up from £14.0 billion ($15.88 billion) in 2021. As a result, increased funding for research and development is contributing to the growth of the Hutchinson-Gilford Progeria Syndrome (HGPS) market.

Leading companies in the Hutchinson-Gilford Progeria Syndrome (HGPS) market are prioritizing the development of advanced farnesyltransferase inhibitors to enhance treatment effectiveness and slow disease progression in affected patients. Farnesyltransferase inhibitors are drugs that block farnesyltransferase, an enzyme responsible for protein modification, helping prevent abnormal cell growth and aging. For instance, in July 2022, Eiger BioPharmaceuticals, a US-based biopharmaceutical company, received marketing authorization from the European Commission for Zokinvy, making it the first and only approved treatment in Europe for Hutchinson-Gilford Progeria Syndrome (HGPS) and processing-deficient progeroid laminopathies (PL) in children and young adults. Zokinvy, an oral disease-modifying agent, demonstrated a 72% reduction in mortality risk and an average life extension of 4.3 years in clinical trials. The European Commission's centralized authorization applies across all 27 EU member states as well as Iceland, Liechtenstein, and Norway.

In May 2024, Sentynl Therapeutics, Inc., a US-based biopharmaceutical company, acquired Zokinvy from Eiger BioPharmaceuticals, Inc. for an undisclosed amount. Through this acquisition, Sentynl aims to address the unmet medical needs of patients suffering from ultra-rare genetic conditions that cause accelerated aging and significantly shorten life expectancy. Eiger BioPharmaceuticals, Inc., a US-based biopharmaceutical company, originally developed Zokinvy (lonafarnib) for the treatment of Hutchinson-Gilford Progeria Syndrome (HGPS).

Major players in the hutchinson-gilford progeria syndrome (hgps) market are National Institutes of Health (NIH), Mount Sinai, Johns Hopkins Hospital, Duke University, Mayo Foundation for Medical Education and Research, Cleveland Clinic, Children's Hospital of Philadelphia, St. Jude Children's Research Hospital, Cincinnati Children's Hospital Medical Center, University of Maryland, Boston Children's Hospital, Children's Hospital Los Angeles, Harvard Medical School, The Scripps Research Institute, Blueprint Genetics, Medicover Hospitals, Sentynl Therapeutics, UCSF Helen Diller Family Comprehensive Cancer Center, Progeria Research Foundation, AnGes MG Inc., and PRG Science & Technology Co. Ltd.

North America was the largest region in the hutchinson-gilford progeria syndrome (HGPS) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in hutchinson-gilford progeria syndrome (HGPS) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the hutchinson-gilford progeria syndrome (HGPS) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The hutchinson-gilford progeria syndrome (HGPS) market consists of revenues earned by entities by providing services such as genetic testing and diagnosis, drug development and clinical trials, specialized medical care and treatment, and patient support and counseling services. The market value includes the value of related goods sold by the service provider or included within the service offering. The hutchinson-gilford progeria syndrome (HGPS) market also includes sales of pharmaceutical drugs, genetic testing kits, medical devices and monitoring equipment, nutritional supplements and special diet products, and assistive mobility devices. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Hutchinson-Gilford Progeria Syndrome (HGPS) Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on hutchinson-gilford progeria syndrome (hgps) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for hutchinson-gilford progeria syndrome (hgps) ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The hutchinson-gilford progeria syndrome (hgps) market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Treatment Type: Farnesyltransferase Inhibitors (Zokinvy (Lonafarnib)); Low-dose Aspirin; Physical And Occupational Therapy; Hearing Aids; Genetic Counseling; Other Treatment Types
• 2) By Route Of Administration: Oral; Injectable; Intravenous; Transdermal
• 3) By Mechanism Of Action: Antisense Oligonucleotides; Crispr-cas9 Gene Editing; Rna Interference; Targeted Drug Delivery Systems
• 4) By End-User: Hospitals; Specialty Clinics; Academic And Research Institutes; Other End-Users
• Subsegments:
• 1) By Farnesyltransferase Inhibitors (Zokinvy (Lonafarnib)): Monotherapy With Lonafarnib; Combination Therapy With Other Drugs
• 2) By Low-dose Aspirin: Cardiovascular Protection; Anti-inflammatory Therapy
• 3) By Physical And Occupational Therapy: Mobility Support And Rehabilitation; Joint And Bone Health Management; Adaptive Equipment For Daily Activities
• 4) By Hearing Aids: Conventional Hearing Aids; Bone-Anchored Hearing Aids (BAHA); Cochlear Implants
• 5) By Genetic Counseling: Family Genetic Testing; Genetic Risk Assessment; Prenatal Counseling And Guidance
• 6) By Other Treatment Types: Stem Cell Therapy; Gene Editing and Therapy; Nutritional Support And Management
• Companies Mentioned: National Institutes of Health (NIH); Mount Sinai; Johns Hopkins Hospital; Duke University; Mayo Foundation for Medical Education and Research
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Hutchinson-Gilford Progeria Syndrome (HGPS) Market Characteristics

3. Hutchinson-Gilford Progeria Syndrome (HGPS) Market Trends And Strategies

4. Hutchinson-Gilford Progeria Syndrome (HGPS) Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Hutchinson-Gilford Progeria Syndrome (HGPS) Growth Analysis And Strategic Analysis Framework

• 5.1. Global Hutchinson-Gilford Progeria Syndrome (HGPS) PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Hutchinson-Gilford Progeria Syndrome (HGPS) Market Growth Rate Analysis
• 5.4. Global Hutchinson-Gilford Progeria Syndrome (HGPS) Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Hutchinson-Gilford Progeria Syndrome (HGPS) Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Hutchinson-Gilford Progeria Syndrome (HGPS) Total Addressable Market (TAM)

6. Hutchinson-Gilford Progeria Syndrome (HGPS) Market Segmentation

• 6.1. Global Hutchinson-Gilford Progeria Syndrome (HGPS) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Farnesyltransferase Inhibitors (Zokinvy (Lonafarnib))
• Low-dose Aspirin
• Physical And Occupational Therapy
• Hearing Aids
• Genetic Counseling
• Other Treatment Types
• 6.2. Global Hutchinson-Gilford Progeria Syndrome (HGPS) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Injectable
• Intravenous
• Transdermal
• 6.3. Global Hutchinson-Gilford Progeria Syndrome (HGPS) Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Antisense Oligonucleotides
• Crispr-cas9 Gene Editing
• Ribonucleic Acid (RNA) Interference
• Targeted Drug Delivery Systems
• 6.4. Global Hutchinson-Gilford Progeria Syndrome (HGPS) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Specialty Clinics
• Academic And Research Institutes
• Other End-Users
• 6.5. Global Hutchinson-Gilford Progeria Syndrome (HGPS) Market, Sub-Segmentation Of Farnesyltransferase Inhibitors (Zokinvy (Lonafarnib)), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Monotherapy With Lonafarnib
• Combination Therapy With Other Drugs
• 6.6. Global Hutchinson-Gilford Progeria Syndrome (HGPS) Market, Sub-Segmentation Of Low-dose Aspirin, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Cardiovascular Protection
• Anti-inflammatory Therapy
• 6.7. Global Hutchinson-Gilford Progeria Syndrome (HGPS) Market, Sub-Segmentation Of Physical And Occupational Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Mobility Support And Rehabilitation
• Joint And Bone Health Management
• Adaptive Equipment For Daily Activities
• 6.8. Global Hutchinson-Gilford Progeria Syndrome (HGPS) Market, Sub-Segmentation Of Hearing Aids, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Conventional Hearing Aids
• Bone-Anchored Hearing Aids (BAHA)
• Cochlear Implants
• 6.9. Global Hutchinson-Gilford Progeria Syndrome (HGPS) Market, Sub-Segmentation Of Genetic Counseling, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Family Genetic Testing
• Genetic Risk Assessment
• Prenatal Counseling And Guidance
• 6.10. Global Hutchinson-Gilford Progeria Syndrome (HGPS) Market, Sub-Segmentation Of Other Treatment Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Stem Cell Therapy
• Gene Editing and Therapy
• Nutritional Support And Management

7. Hutchinson-Gilford Progeria Syndrome (HGPS) Market Regional And Country Analysis

• 7.1. Global Hutchinson-Gilford Progeria Syndrome (HGPS) Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Hutchinson-Gilford Progeria Syndrome (HGPS) Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Hutchinson-Gilford Progeria Syndrome (HGPS) Market

• 8.1. Asia-Pacific Hutchinson-Gilford Progeria Syndrome (HGPS) Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Hutchinson-Gilford Progeria Syndrome (HGPS) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Hutchinson-Gilford Progeria Syndrome (HGPS) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Hutchinson-Gilford Progeria Syndrome (HGPS) Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Hutchinson-Gilford Progeria Syndrome (HGPS) Market

• 9.1. China Hutchinson-Gilford Progeria Syndrome (HGPS) Market Overview
• 9.2. China Hutchinson-Gilford Progeria Syndrome (HGPS) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Hutchinson-Gilford Progeria Syndrome (HGPS) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Hutchinson-Gilford Progeria Syndrome (HGPS) Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Hutchinson-Gilford Progeria Syndrome (HGPS) Market

• 10.1. India Hutchinson-Gilford Progeria Syndrome (HGPS) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Hutchinson-Gilford Progeria Syndrome (HGPS) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Hutchinson-Gilford Progeria Syndrome (HGPS) Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Hutchinson-Gilford Progeria Syndrome (HGPS) Market

• 11.1. Japan Hutchinson-Gilford Progeria Syndrome (HGPS) Market Overview
• 11.2. Japan Hutchinson-Gilford Progeria Syndrome (HGPS) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Hutchinson-Gilford Progeria Syndrome (HGPS) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Hutchinson-Gilford Progeria Syndrome (HGPS) Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Hutchinson-Gilford Progeria Syndrome (HGPS) Market

• 12.1. Australia Hutchinson-Gilford Progeria Syndrome (HGPS) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Hutchinson-Gilford Progeria Syndrome (HGPS) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Hutchinson-Gilford Progeria Syndrome (HGPS) Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Hutchinson-Gilford Progeria Syndrome (HGPS) Market

• 13.1. Indonesia Hutchinson-Gilford Progeria Syndrome (HGPS) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Hutchinson-Gilford Progeria Syndrome (HGPS) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Hutchinson-Gilford Progeria Syndrome (HGPS) Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Hutchinson-Gilford Progeria Syndrome (HGPS) Market

• 14.1. South Korea Hutchinson-Gilford Progeria Syndrome (HGPS) Market Overview
• 14.2. South Korea Hutchinson-Gilford Progeria Syndrome (HGPS) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Hutchinson-Gilford Progeria Syndrome (HGPS) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Hutchinson-Gilford Progeria Syndrome (HGPS) Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Hutchinson-Gilford Progeria Syndrome (HGPS) Market

• 15.1. Western Europe Hutchinson-Gilford Progeria Syndrome (HGPS) Market Overview
• 15.2. Western Europe Hutchinson-Gilford Progeria Syndrome (HGPS) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Hutchinson-Gilford Progeria Syndrome (HGPS) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Hutchinson-Gilford Progeria Syndrome (HGPS) Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Hutchinson-Gilford Progeria Syndrome (HGPS) Market

• 16.1. UK Hutchinson-Gilford Progeria Syndrome (HGPS) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Hutchinson-Gilford Progeria Syndrome (HGPS) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Hutchinson-Gilford Progeria Syndrome (HGPS) Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Hutchinson-Gilford Progeria Syndrome (HGPS) Market

• 17.1. Germany Hutchinson-Gilford Progeria Syndrome (HGPS) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Hutchinson-Gilford Progeria Syndrome (HGPS) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Hutchinson-Gilford Progeria Syndrome (HGPS) Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Hutchinson-Gilford Progeria Syndrome (HGPS) Market

• 18.1. France Hutchinson-Gilford Progeria Syndrome (HGPS) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Hutchinson-Gilford Progeria Syndrome (HGPS) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Hutchinson-Gilford Progeria Syndrome (HGPS) Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Hutchinson-Gilford Progeria Syndrome (HGPS) Market

• 19.1. Italy Hutchinson-Gilford Progeria Syndrome (HGPS) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Hutchinson-Gilford Progeria Syndrome (HGPS) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Hutchinson-Gilford Progeria Syndrome (HGPS) Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Hutchinson-Gilford Progeria Syndrome (HGPS) Market

• 20.1. Spain Hutchinson-Gilford Progeria Syndrome (HGPS) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Hutchinson-Gilford Progeria Syndrome (HGPS) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Hutchinson-Gilford Progeria Syndrome (HGPS) Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Hutchinson-Gilford Progeria Syndrome (HGPS) Market

• 21.1. Eastern Europe Hutchinson-Gilford Progeria Syndrome (HGPS) Market Overview
• 21.2. Eastern Europe Hutchinson-Gilford Progeria Syndrome (HGPS) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Hutchinson-Gilford Progeria Syndrome (HGPS) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Hutchinson-Gilford Progeria Syndrome (HGPS) Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Hutchinson-Gilford Progeria Syndrome (HGPS) Market

• 22.1. Russia Hutchinson-Gilford Progeria Syndrome (HGPS) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Hutchinson-Gilford Progeria Syndrome (HGPS) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Hutchinson-Gilford Progeria Syndrome (HGPS) Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Hutchinson-Gilford Progeria Syndrome (HGPS) Market

• 23.1. North America Hutchinson-Gilford Progeria Syndrome (HGPS) Market Overview
• 23.2. North America Hutchinson-Gilford Progeria Syndrome (HGPS) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Hutchinson-Gilford Progeria Syndrome (HGPS) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Hutchinson-Gilford Progeria Syndrome (HGPS) Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Hutchinson-Gilford Progeria Syndrome (HGPS) Market

• 24.1. USA Hutchinson-Gilford Progeria Syndrome (HGPS) Market Overview
• 24.2. USA Hutchinson-Gilford Progeria Syndrome (HGPS) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Hutchinson-Gilford Progeria Syndrome (HGPS) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Hutchinson-Gilford Progeria Syndrome (HGPS) Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Hutchinson-Gilford Progeria Syndrome (HGPS) Market

• 25.1. Canada Hutchinson-Gilford Progeria Syndrome (HGPS) Market Overview
• 25.2. Canada Hutchinson-Gilford Progeria Syndrome (HGPS) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Hutchinson-Gilford Progeria Syndrome (HGPS) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Hutchinson-Gilford Progeria Syndrome (HGPS) Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Hutchinson-Gilford Progeria Syndrome (HGPS) Market

• 26.1. South America Hutchinson-Gilford Progeria Syndrome (HGPS) Market Overview
• 26.2. South America Hutchinson-Gilford Progeria Syndrome (HGPS) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Hutchinson-Gilford Progeria Syndrome (HGPS) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Hutchinson-Gilford Progeria Syndrome (HGPS) Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Hutchinson-Gilford Progeria Syndrome (HGPS) Market

• 27.1. Brazil Hutchinson-Gilford Progeria Syndrome (HGPS) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Hutchinson-Gilford Progeria Syndrome (HGPS) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Hutchinson-Gilford Progeria Syndrome (HGPS) Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Hutchinson-Gilford Progeria Syndrome (HGPS) Market

• 28.1. Middle East Hutchinson-Gilford Progeria Syndrome (HGPS) Market Overview
• 28.2. Middle East Hutchinson-Gilford Progeria Syndrome (HGPS) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Hutchinson-Gilford Progeria Syndrome (HGPS) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Hutchinson-Gilford Progeria Syndrome (HGPS) Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Hutchinson-Gilford Progeria Syndrome (HGPS) Market

• 29.1. Africa Hutchinson-Gilford Progeria Syndrome (HGPS) Market Overview
• 29.2. Africa Hutchinson-Gilford Progeria Syndrome (HGPS) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Hutchinson-Gilford Progeria Syndrome (HGPS) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Hutchinson-Gilford Progeria Syndrome (HGPS) Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Hutchinson-Gilford Progeria Syndrome (HGPS) Market Competitive Landscape And Company Profiles

• 30.1. Hutchinson-Gilford Progeria Syndrome (HGPS) Market Competitive Landscape
• 30.2. Hutchinson-Gilford Progeria Syndrome (HGPS) Market Company Profiles
  • 30.2.1. National Institutes of Health (NIH) Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Mount Sinai Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Johns Hopkins Hospital Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Duke University Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Mayo Foundation for Medical Education and Research Overview, Products and Services, Strategy and Financial Analysis

31. Hutchinson-Gilford Progeria Syndrome (HGPS) Market Other Major And Innovative Companies

• 31.1. Cleveland Clinic
• 31.2. Children's Hospital of Philadelphia
• 31.3. St. Jude Children's Research Hospital
• 31.4. Cincinnati Children's Hospital Medical Center
• 31.5. University of Maryland
• 31.6. Boston Children's Hospital
• 31.7. Children's Hospital Los Angeles
• 31.8. Harvard Medical School
• 31.9. The Scripps Research Institute
• 31.10. Blueprint Genetics
• 31.11. Medicover Hospitals
• 31.12. Sentynl Therapeutics
• 31.13. UCSF Helen Diller Family Comprehensive Cancer Center
• 31.14. Progeria Research Foundation
• 31.15. AnGes MG Inc.

32. Global Hutchinson-Gilford Progeria Syndrome (HGPS) Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Hutchinson-Gilford Progeria Syndrome (HGPS) Market

34. Recent Developments In The Hutchinson-Gilford Progeria Syndrome (HGPS) Market

35. Hutchinson-Gilford Progeria Syndrome (HGPS) Market High Potential Countries, Segments and Strategies

• 35.1 Hutchinson-Gilford Progeria Syndrome (HGPS) Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Hutchinson-Gilford Progeria Syndrome (HGPS) Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Hutchinson-Gilford Progeria Syndrome (HGPS) Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer